CytomX Therapeutics (CTMX) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Company overview and strategic positioning

• Pioneered masked antibody technology with over a decade of experience and three clinical-stage programs across multiple modalities.

• Maintains five major pharma partnerships, including Regeneron, Moderna, BMS, and Astellas, supporting a strong financial position through 2025.

• Differentiates through deep protease biology expertise, enabling optimized next-generation masked therapeutics.

• Strategic focus on retaining economic rights for key wholly owned programs and targeting high unmet needs.

• Multi-modality approach provides flexibility in addressing diverse oncology targets.

Key partnerships and collaborations

• Regeneron partnership focuses on T cell engaging bispecifics, reflecting high scientific standards.

• Moderna collaboration explores mRNA-encoded masked therapeutics, leveraging broad modality experience.

• Amgen partnership led to the development of CX-904, a T cell engager targeting EGFR, with ongoing clinical progress.

• Astellas partnership achieved two preclinical milestones in bispecific immunotherapies, with potential commercial opt-in rights.

Lead program CX-904 (EGFR CD3 T cell engager)

• Demonstrated manageable safety profile in phase Ia, with minimal cytokine release syndrome and low-grade EGFR-related toxicities.

• Early efficacy signals in pancreatic cancer, with confirmed partial responses and stable disease in a small cohort.

• Limited activity observed in colorectal cancer; future focus on pancreatic, head and neck, and lung cancers.

• Next steps include further enrollment and data generation in these indications, with a program update expected by year-end and detailed data in the first half of 2025.

• Amgen holds an option to co-develop globally as the program advances to phase 1b.